IL1B and lung carcinoma: This possibility was supported by the finding of a significantly reduced incidence of lung cancer and decreased lung cancer mortality in a trial after the activity of the major product of inflammasome activation, IL‐1β, was inhibited by a specific antibody, canakinumab [80].